Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Cytopia Research Pty Ltd |
---|---|
Information provided by: | Cytopia Research Pty Ltd |
ClinicalTrials.gov Identifier: | NCT00650949 |
This study seeks to (i) determine the safe dose of CYT997 when given in combination with carboplatin and etoposide in patients with relapsed glioblastoma multiforme (glioma) and (ii) to determine whether the combination of CYT997 with carboplatin and etoposide is a useful treatment for glioma.
Condition | Intervention | Phase |
---|---|---|
Glioblastoma Multiforme Relapsed |
Drug: CYT997 Drug: Carboplatin Drug: Etoposide phosphate |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase Ib/II Study of CYT997 in Combination With Carboplatin and Etoposide in Relapsed Glioblastoma Multiforme |
Estimated Enrollment: | 35 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: CYT997
Escalating doses (150mg/m2 to 200mg/m2), 24 hour intravenous infusion on day 2 of a 21 day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
Drug: Carboplatin
Intravenous infusion over 1h at AUC=5 on day 1 of a 21 day cycle
Drug: Etoposide phosphate
Intravenous push at 113.6mg/m2 on days 1, 2 and 3 of a 21 day cycle
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have adequate organ and marrow function as defined below:
Exclusion Criteria:
Contact: Carmel O'Kane, RN | +61397847211 | cokane@phcn.vic.gov.au |
Australia, Victoria | |
Monash Medical Centre | Recruiting |
Melbourne, Victoria, Australia | |
Contact: Carmel O'Kane, RN +61397847211 cokane@phcn.vic.gov.au |
Study Chair: | Jason Lickliter, MD | Frankston Hospital |
Responsible Party: | Cytopia Research Pty Ltd ( Dr Gregg Smith, Director: Drug Development ) |
Study ID Numbers: | CCL08001 |
Study First Received: | March 27, 2008 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00650949 |
Health Authority: | United States: Food and Drug Administration; Australia: Therapeutic Goods Administration |
Glioblastoma multiforme glioma |
Neuroectodermal Tumors Glioblastoma Glioblastoma multiforme Astrocytoma Neoplasms, Germ Cell and Embryonal Neuroepithelioma |
Carboplatin Glioma Etoposide phosphate Etoposide Neoplasms, Glandular and Epithelial |
Neoplasms Neoplasms by Histologic Type Antineoplastic Agents Therapeutic Uses |
Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Antineoplastic Agents, Phytogenic Pharmacologic Actions |